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Over 20% of human cancers worldwide are associated with infectious agents,
including viruses, bacteria, and parasites. Various methods have been used to
identify human tumor viruses, including electron microscopic observations of viral
particles, immunologic screening, cDNA library screening, nucleic acid hybridization,
consensus PCR, viral DNA array chip, and representational difference analysis. With
the Human Genome Project, a large amount of genetic information from humans
and other organisms has accumulated over the last decade. Utilizing the available
genetic databases, Feng et al. (2007) developed digital transcriptome subtraction
(DTS), an in silico method to sequentially subtract human sequences from tissue or
cellular transcriptome, and discovered Merkel cell polyomavirus (MCV) from Merkel cell
carcinoma. Here, we review the background and methods underlying the human tumor
virus discoveries and explain how DTS was developed and used for the discovery
of MCV.
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INTRODUCTION
Approximately 20% of human cancers worldwide are associated with infectious agents, including
parasites, bacteria, and viruses (Parkin, 2006). In 12% of cancers, seven different viruses have been
causally linked to human oncogenesis (Table 1): Epstein–Barr virus (EBV), hepatitis B virus (HBV),
human T-lymphotropic retrovirus type 1 (HTLV-1), high-risk human papillomaviruses (HPV),
hepatitis C virus (HCV), Kaposi’s sarcoma herpesvirus (KSHV), and Merkel cell polyomavirus
(MCV). The epidemiological and clinical information provides clues that indicate whether
an infectious agent is involved in the development of cancer. Cancers that are related to
immunosuppression, for example, are candidates for being caused by tumor viruses (Grulich et al.,
2007). During the 20th century, various methods, ranging from the classical electron microscopic
observation to the advanced molecular biology techniques, were used to identify cancer-causing
viruses. Here, we will review the background and methods underlying the tumor virus discoveries
during the past century as well as the newest virus discovery strategy, digital transcriptome
subtraction (DTS) that we used to discover MCV.
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TABLE 1 | Discovery methods of human tumor viruses.
Virus Initial discovery method Year Associated human cancers Reference
Epstein–Barr virus Electron microscopic observation 1964 Burkitt’s lymphoma, Hodgkin’s lymphoma,
post-transplantation lymphoproliferative
disorder, and nasopharyngeal carcinoma,
gastric carcinoma
Epstein et al., 1964
Hepatitis B Immunology 1967 Hepatocellular carcinoma (HCC) Blumberg et al.,
1967
HTLV-1 Cell culture 1980 Adult T cell leukemia Poiesz et al., 1980
Papillomavirus (high risk 16 and 18) Nucleotide acid hybridization 1983–1984 Cervical carcinoma, head and neck
carcinoma, anogenital cancer
Durst et al., 1983;
Boshart et al., 1984
Hepatitis C cDNA cloning 1989 HCC Choo et al., 1989
Kaposi’s sarcoma associated herpesvirus Representational difference analysis 1994 Kaposi’s sarcoma, primary effusion
lymphoma, Castleman’s disease
Chang et al., 1994
Merkel cell polyomavirus Digital transcriptome subtraction 2008 Merkel cell carcinoma Feng et al., 2008
METHODS USED FOR THE HUMAN
TUMOR VIRUS DISCOVERIES
Cell Culture and Electron Microscopy
By the early 1960s, many viruses were known to cause tumors
in animals (Javier and Butel, 2008), but none had been
identified in human cancers. Burkitt (1958) first described his
eponymous lymphoma in 1958 as a sarcoma involving the jaws
of African children and hypothesized that the cancer’s geographic
distribution might implicate some infectious agent as an
etiologic factor in disease development. When the first Burkitt’s
lymphoma-derived cell line was established in vitro and examined
by electron microscopy, obvious herpesvirus morphology was
readily observed (Epstein et al., 1964). Biological examinations
demonstrated that this was a new human herpesvirus, which
became known as the EBV after the cell line in which it was
discovered (Epstein et al., 1965).
The human T-lymphotropic virus type 1 (HTLV-1), the first
known human retrovirus, was also identified in cell culture
(Poiesz et al., 1980). Retrovirus particles with type C morphology
were observed in thin-section electron micrographs of fixed,
pelleted cellular materials from two T-cell lymphoblastoid cell
lines (HUT102 and CTCL-3) and peripheral blood lymphocytes
from a patient with a cutaneous T-cell lymphoma. Mature
particles were 100–110 nm in diameter, and consisted of an
electron-dense core separated by an electron-lucent region from
an outer membrane. Similar type C particles were identified
in MT-1 cells derived from Japanese patients with adult T cell
leukemia (ATL), which is now known to be caused by HTLV-1
(Hinuma et al., 1981). Indirect immunofluorescence staining was
also used in the studies of ATL. A unique antigen was identified in
MT-1 cells derived from ATL that was not found in other human
lymphoid cell lines. All 44 examined ATL patients had positive
serological reactions for this antigen.
In general, it is very rare that human cancer arises
directly from the acute consequences of viral infection.
Tumorigenesis usually occurs after a latency period of 15–
40 years. However, a special exception is the X-chromosome-
linked lymphoproliferative disorder (XLP) found in some
EBV-infected patients. Mutated immune response genes leave
susceptible males unable to respond to interferon (IFN) signaling,
which can in turn lead to the development of an acute
lymphoproliferative disease as a consequence of EBV replication
(Kutok and Wang, 2006). Most viruses do not replicate efficiently
in common laboratory cell lines due to the innate immune
system, which controls IFN signaling. By targeting molecules in
the IFN signaling pathway through knockout technology or RNA
interference, it is possible to produce cells that are permissive
for viral replication. Cell culture models with a defective IFN
signaling pathway are useful for novel virus identification and
characterization, especially in monitoring for cytopathic effects
(CPE). The robust replication of a virus often gives rise to
CPE, which involves morphological changes in the host cell,
such as cell rounding, disorientation, swelling or shrinking,
detachment from the culture surface, and cell death, and may
indicate that the cells being studied are a good model in which
to amplify the genome of the putative virus. This strategy was
successfully used in acute infection with African green monkey
kidney cells (Vero, a IFN-deficient cell) to identify previously
uncharacterized human coronavirus (HCoV-NL63; van der Hoek
et al., 2004). Humanized mice have also been developed to study
viral infection in a systemic setting (Lassnig et al., 2005). In this
study, viral replication was markedly enhanced in the offspring of
mice with human viral receptor genes that were crossed with IFN
unresponsive Stat1−/− mice. Such cell and animal models, which
take advantage of advanced techniques in molecular biology and
genetic engineering, have the potential to provide novel insights
into the biology of otherwise unculturable infectious agents and
to identify the tumorigenic potential of a virus.
Immunologic Methods to Detect Viral
Antigen
Tissue culture, animal inoculation, and other virological methods
were all applied unsuccessfully in early attempts to identify HBV
(Blumberg, 1977). Blumberg et al. (1965) performed a systematic
study of the sera collected from leukemia and hemophilia
patients who had experienced frequent blood transfusions in
order to detect precipitating iso-antibodies against unknown
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antigens found in donor serum. The ‘Australia antigen’ was
identified in the serum of an Australian Aborigine as being
a target of precipitating antibodies generated in the serum of
transfusion patients (Blumberg et al., 1965). It was found to
be rare in normal Americans, but was common in normal
people from Africa, Asia, and Oceania. These data led some
to hypothesize a relationship between leukemia, the unknown
agent, and genetic polymorphism(s) in Australia. Subsequently,
the Australian antigen was revealed to be an antigen shared
by multiple hepatitis patients (Blumberg et al., 1967; Prince,
1968). Virus-like particles containing ‘Australian antigen’ on their
surface were eventually found by electronic microscopy in the
blood of three patients with ‘serum hepatitis’ (Dane et al., 1970;
Jokelainen et al., 1970). These findings were the first indication
that the disease now known as hepatitis B is caused by a virus
(HBV).
The discovery of HCV was an extraordinary achievement,
because isolation of the viral genome did not rely on previously
visualized viral particles, growth of the virus in vitro, or
development of an immunological assay. Patients who had
transfusion-associated hepatitis were described, despite being
negative for hepatitis A and B antigens, which suggested the
existence of another, unidentified infectious agent (Feinstone
et al., 1975). Although several immunologic and serologic assays
were developed, none was a specific, reliable serologic marker
for this unknown hepatitis antigen. However, administration of
the putative infectious reagent induced non-A, non-B hepatitis
in chimpanzees, which confirmed that an infectious agent was
likely responsible for the disease (Tabor et al., 1978). A decade
after the development of the chimpanzee disease model, Alter and
Houghton (2000), utilizing novel methodologies in molecular
biology, conducted a blind immunoscreen using a recombinant
phage expression library. In searching for an unknown virus in
these non-A, non-B hepatitis patients, a randomly primed cDNA
library was constructed from the plasma of chimpanzees that had
been injected with serum from non-A, non-B hepatitis patients.
cDNA was inserted into the bacteriophage λgt11 and expressed
in Escherichia coli. The expressed proteins were then screened
against serum from an infected non-A, non-B hepatitis patient.
Among millions of the clones screened, one clone encoded an
antigen that showed specific seroreactivity in non-A, non-B
hepatitis patients. The putative virus was shown to contain a
positive-strand RNA molecule of about 10,000 nucleotides that
belongs to the Flaviviridae family (Choo et al., 1989). Novel
virus discovery by screening recombinant expression libraries
from infected tissues against patient sera represented a significant
breakthrough. However, library screenings are also laborious, as
hundreds of millions of bacterial cDNA clones had to be screened
(Alter and Houghton, 2000).
Cross-hybridization to Identify Related
Viruses
The Papillomaviridae comprise a super-family with several 100
members, most of which were identified in birds and mammals
(de Villiers et al., 2004). Papillomaviruses are highly host-
tropic and tissue-specific, causing small benign tumors known
as papillomas or warts. HPV particles were observed by electron
microscopy in cervical dysplasia (Della Torre et al., 1978;
Meisels et al., 1981), whereas in cervical intraepithelial lesions
and cervical cancer specimens, virus particles are not generally
observed due to the viral integration into host genome. High-
risk HPV 16 was isolated from an invasive cervical cancer
by cross-hybridization with HPV type 11 DNA under non-
stringent conditions (Durst et al., 1983). Using virus-specific
probes, HPV 16 presence was confirmed in precursor lesion
of malignant tumors (Ikenberg et al., 1983). High-risk HPV18
was subsequently identified by low stringency hybridization with
HPV 8, 9, 10, and 11-related sequences (Boshart et al., 1984).
zur Hausen’s (1999) research group identified both HPV16 and
18, which together are responsible for approximately 70% of
invasive cervical cancers (de Sanjose et al., 2010). His group
further demonstrated that HPV DNA is integrated into the host
genome in cervical cancer cell lines and that viral E6 and E7
genes are expressed in cervical cancer tumors (Schwarz et al.,
1985).
Nucleic acid hybridization with a single or few probes
is restricted by its ability to detect only a limited number
of candidate viruses. To obviate this problem, Virochip was
invented to detect a broad spectrum of viruses in a single
analysis (Wang et al., 2002). The Virochip was successfully used
to identify a previously uncharacterized coronavirus isolated
from a SARS patient during the outbreak of the severe acute
respiratory syndrome (SARS; Rota et al., 2003). For the tumor
virus identification, the Virochip was used to screen RNA samples
from prostate tumors. A novel gammaretrovirus, Xenotropic
murine leukemia virus-related virus (XMRV), which is closely
related to the xenotropic murine leukemia viruses (MuLVs),
was found in patients with prostate cancers (Urisman et al.,
2006), and chronic fatigue syndrome (Lombardi et al., 2009).
XMRV is detected in malignant prostate epithelium by using
quantitative PCR assay and immunohistochemistry with an anti-
XMRV specific antiserum, raising the possibility of the virus
may indirectly support tumorigenesis (Schlaberg et al., 2009).
However, subsequent reports disprove the etiologic connection
between XMRV infection and these two diseases (Fischer et al.,
2008; Hohn et al., 2009; Lee et al., 2012). XMRV was found to have
arisen during the passage of a human prostate cancer in mice, as
a result of recombination between two endogenous MuLVs from
the mouse cells. The resulting XMRV infected human prostate
cancer cells due to its xenotropic host range (Paprotka et al.,
2011).
With the widespread usage of PCR and availability of
extensive viral sequences, it is possible to combine short-primer
hybridization and the power of PCR to amplify potential viral
sequences. This method is commonly known as consensus
sequence-base PCR or degenerate PCR. Primer sequences are
designed based on a conserved region of a viral genome. Human
hepatitis G virus was identified by amplifying a segment of a
putative helicase gene with consensus primers from hepatitis A,
B, and C virus (Simons et al., 1995a). As with genomic nucleotide
acid hybridization, consensus PCR/degenerate PCR relies on
known viral sequences, and as such has limitations in identifying
novel viruses. Moreover, false-positives due to non-specific
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amplification and PCR contamination may introduce costly and
fruitless downstream analyses. Thus, careful optimization of
reaction and primer annealing temperatures and the use of nested
or semi-nested strategies, as well as the use of known viruses as
positive controls, are necessary.
Differential Display Strategy in Viral
Pathogen Discovery
The recent molecular techniques for virus discovery are solely
based on nucleic acids—rather than conventional viral particle
morphology, in vitro cell culture, or serological assays—but
must be used in conjunction with strong epidemiologic evidence
(Gao and Moore, 1996). These methods identify discrepancies
in nucleotide sequence between disease-associated tissue
and normal tissue by subtractive strategies. Representational
difference analysis (RDA) combines physical subtractive
hybridization with gene amplification to detect differences
between tumor genomic DNA and that of normal cells (Lisitsyn
et al., 1993). Epidemiologic evidence indicated that Kaposi’s
sarcoma may be caused by a pathogen other than human
immunodeficiency virus (HIV; Beral et al., 1990, 1992). By using
RDA, novel viral fragments were identified in AIDS patients
and further characterized as human Kaposi’s sarcoma associated
herpesvirus (KSHV; Chang et al., 1994; Moore et al., 1996).
RDA has also been used to successfully identify hepatitis G
virus (Simons et al., 1995b) and Torque Teno virus (TTV) in
non-A–E hepatitis patients (Nishizawa et al., 1997). While RDA
was used to successfully identify these viruses, this technique
relies heavily on the non-diseased tissue controls and is not
quantitative.
In Silico Subtraction Approach Using
Nucleic Acid Database
With initiation of the Human Genome Project, the nucleic
acid databases for humans and many other organisms rapidly
expanded. Taking advantage of this new wealth of data, Weber
et al. (2002) developed an in silico subtraction approach capable
of identifying non-human sequences in ‘human’ expressed-
sequence tag (EST) libraries. In this computational subtraction
technique, sequences with high similarity to the human genome
are subtracted from cDNA libraries, such that the remaining
data are enriched for sequences of non-human origin. Weber
et al. (2002) directly identified multiple human tumor viruses
erroneously deposited as human ESTs in GenBank, including
EBV, HBV, HPV type 16 and 18, HCV, and KSHV. Viral
sequences were also found in data deposited from hepatocellular
carcinoma (HCC) and cervical carcinoma cell lines: HBV
sequences represented 0.1% of deposited HCC data, while HPV18
sequences accounted for 0.03% of the cervical carcinoma library.
The same group also generated a cDNA library from a patient
with post-transplant lymphoproliferative disorder (PTLD; Xu
et al., 2003). A total of 27,840 cDNA sequences were generated
and filtered by computational subtraction against known human
sequences, leaving 32 non-matching sequences. Among these
sequences, 10 (accounting for 0.03% of total sequences analyzed)
were from EBV viruses. Taken together, these results suggest that
it is possible to identify viral sequences by sampling fewer than
10,000 sequences.
DEVELOPMENT OF DIGITAL
TRANSCRIPTOME SUBTRACTION
Feng et al. (2007) developed DTS as a quantitative means to
search for viral infection in human cancers (Figure 1) (Feng
et al., 2007). High quality sequences are extracted with a high
stringency score (Phred > = 20) to avoid sequencing errors, and
all sequences artificially used in the cDNA library preparation,
such as sequencing primers, are removed. All sequences matching
human databases are computationally subtracted to leave ‘non-
human’ candidates. There are approximately 200,000 mRNA
transcripts in a cell (Bishop et al., 1974; Velculescu et al., 1999),
which correspond to five transcripts per million (TPM) for a
single transcript per cell. In theory, one can analyze the whole
transcriptome to search for viral etiology in human cancers. Thus,
if no viral transcript is found, the possibility of a virus expressing
transcript in a given tumor can be excluded above a certain
threshold level.
Long serial analysis of gene expression (L-SAGE) was used
to sample the cellular transcriptome for the presence of viral
transcripts. L-SAGE quantitatively concatenates ∼21 bp cDNA
tags from the 3′ end of mRNA transcripts, allowing for the
measurement of gene expression via high-throughput sequencing
(Figure 1) (Saha et al., 2002). When they performed a pilot
analysis of DTS on 9,026 SAGE tags from an expression library of
BCBL-1 cells infected with KSHV, only three candidate sequences
were identified as being of non-human origin: two of these
sequences belonged to KSHV transcripts and the third belonged
to an unannotated human expression sequence tag, as confirmed
by additional experiments. Overall, 0.24% of transcripts from
this cell line were of viral origin. DTS was then applied to
258,302 SAGE tags from squamous cell conjunctival carcinoma
(SCCC), a cancer strongly associated with immunosuppression
(Figure 1). Only 21 of these sequences did not align to human
databases, excluding one KSHV tag as an internal control. All
21 candidates were ruled out as viral sequences by further
experimental examination (Feng et al., 2007). This analysis shows
that it is unlikely that distinguishable viral transcripts are present
in SCCC at 20 TPM or higher, which is the equivalent of
approximately four transcripts per cell.
MERKEL CELL POLYOMAVIRUS
DISCOVERY BY DTS
We further performed high-throughput sequencing on
cDNA libraries constructed from Merkel cell carcinoma
(MCC), a malignant skin tumor frequently found among
immunosuppressed, transplant, and AIDS patients (Feng et al.,
2008). A total of 395,734 sequences were subtracted through
DTS analysis, leaving 2,395 ‘non-human’ sequences (Figure 1).
One transcript was similar to but distinct from African green
monkey lymphotropic polyomavirus (LPV) and human BK
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FIGURE 1 | Digital transcriptome subtraction (DTS). L-SAGE libraries were constructed from BCBL1, a KSHV positive cell line and squamous cell conjunctival
carcinoma (SCCC), and short cDNA tags were sequenced for whole transcriptome analysis. High throughput sequencing (HTS) was performed on cDNA libraries
from human Merkel cell carcinoma (MCC).
polyomavirus T antigen sequences, defining a new polyomavirus,
MCV. Subsequently, we sequenced the complete closed circular
genome of MCV (5,387 bp), which encodes a T antigen locus, late
gene cassette for viral capsids, and replication origin sequences.
MCV is the first human member of the murine polyomavirus
subgroup, and shares highest homology with LPV and a new
polyomavirus recently isolated from orangutans (Groenewoud
et al., 2010). Overall, DTS is a simple screening method to
discover novel viral nucleic acids in a quantitative manner with
high throughput sequencing. We found MCV transcripts in
MCC at a level of 10 TPM or approximately five transcripts per
cell and can exclude distinguishable viral transcripts in SCCC at
20 TPM or higher, which is the equivalent of approximately four
transcripts per cell. This provides, for the first time, quantitative
evidence against some classes of viral etiology when no viral
transcripts are found, thereby reducing the uncertainty involved
in new pathogen discovery.
MCV IS THE FIRST HUMAN
POLYOMAVIRUS CAUSING MCC
Virus discovery is only the first step to determining the etiology
behind a disease. The detection of nucleic acid is not sufficient to
prove causality. Our initial discovery of MCV demonstrated that
the MCV genome is clonally integrated in ∼80% of MCC tumor
cell DNA (Feng et al., 2008). Similar to other polyomaviruses,
the MCV T antigen locus encodes for three major overlapping
transcripts: large T (LT), small T (sT), and 57 kT antigens (Shuda
et al., 2008). With respect to other well-studied polyomavirus
T antigens, MCV LT has conserved N-terminus DnaJ and Rb
binding domains, as well as C-terminus origin binding (OBD)
and helicase domains, which are required for viral replication.
MCV sT has a conserved PP2A binding domain (Shuda et al.,
2008). Our viral sequence analysis in MCC tumors revealed
that integrated MCV LT antigens are C-terminally truncated by
tumor-specific mutations, which results in the loss of helicase
function, whereas MCV sT remains intact (Shuda et al., 2008).
This indicates that MCV is replication-defective in tumors and
not a passenger virus that secondarily infects MCC tumors. We
developed monoclonal antibodies, which specifically recognize
MCV LT or MCV sT and carried out immunohistochemistry
using these antibodies in MCC tissue microarrays. We identified
that approximately ∼70% of MCC tumors express the truncated
LT and sT proteins consistent with their role as directly
transforming oncoproteins in MCC cancers (Shuda et al., 2009,
2011).
We identified three MCC cell lines harboring clonally
integrated MCV, expressing both truncated LT and sT proteins
(Houben et al., 2010; Guastafierro et al., 2013). If MCV is a direct
viral carcinogen that causes most cases of MCC, we anticipate
that its viral oncogene expression is necessary for the growth
of MCC cells. The panT antigen knockdown (both LT and sT)
by shRNA results in G0/G1 cell cycle arrest in MCV-positive
MCC tumor cells and non-apoptotic cell death as measured by
caspase cleavage (Houben et al., 2010). To further assess the
importance of individual T antigens in MCC, we exploited an
shRNA that knocks down sT antigen alone. Knockdown of MCV
sT expression abolished tumor cell growth capacity (Shuda et al.,
2011). On the other hand, Houben et al. (2015) demonstrated that
shRNA knockdown of MCV LT alone also inhibits MCV-positive
MCC cell proliferation. These results indicate that both MCV sT
and LT play critical roles in the maintenance of a tumorigenic
phenotype in MCC cells.
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Our in vitro transformation studies demonstrated that MCV
sT expression alone is sufficient to transform immortalized
rodent fibroblast cell lines in a soft agar assay, while MCV LT
expression was not (Shuda et al., 2011). MCV LT expression,
however, promoted cell proliferation in human fibroblasts
through its Rb binding domain (Cheng et al., 2013; Richards et al.,
2015). Further, multiple groups demonstrated the oncogenic
activities of MCV T antigen in transgenic mouse models. The
MCC-derived MCV T antigen expression in mice, driven by
the keratin 14 promoter induces papillomatosis (Spurgeon et al.,
2015). MCV sT expression using a keratin 5 promoter also
induces hyperproliferative lesions (Verhaegen et al., 2015). We
have also demonstrated that MCV sT expression by the ubiquitin
promoter in p53 null mice induces high-grade tumors in spleen
and liver tissues (Shuda et al., 2015). These results are consistent
with MCV being a human tumor virus encoding T antigen viral
oncoproteins.
Among 13 known human polyomaviruses, eleven have been
identified over the past 9 years by molecular technologies and
next generation DNA sequencing (DeCaprio and Garcea, 2013;
Rinaldo and Hirsch, 2013; Mishra et al., 2014). While JC virus
and SV40 are suspected to play a role in human cancers, the viral
copy numbers in the associated tumors are very low (less than one
copy per cell; Gordon et al., 2002; Rollison et al., 2005). Recently,
to survey for the presence of human polyomaviruses in cancer,
Toptan et al. (2016) developed the immunohistochemistry-based
pan-human polyomavirus screening that can detect T antigen
protein expression of all known human polyomaviruses including
SV40. However, the study did not find any evidence of the
polyomavirus T antigen expression in the 1,184 various tumor
cases except the MCV T antigen expression in MCC tumors
(Toptan et al., 2016). Thus MCV is the only polyomavirus
strongly linked to a human cancer at present.
CONCLUDING REMARKS
Identification of ‘non-human’ sequences from a whole
transcriptome does not necessarily indicate the presence of
other genomes in human disease, as contamination from sample
preparation may introduce some ‘non-human’ sequences.
The existence of such sequences is only meaningful in the
context of a strong association with human disease. Koch’s
postulates and their revisions provide a valid standard for
judging disease causation (Fredricks and Relman, 1996). In
spite of acute infection, tumorigenesis usually occurs after a
long latency period. To move from association to causation for
putatively carcinogenic viral agents, zur Hausen (1999) has also
proposed new criteria for defining a causal role of an infection
in human cancers: (1) strong epidemiological plausibility and
evidence that a viral infection represents a risk factor for the
development of a specific tumor; (2) the consistent presence and
persistence of the ‘non-human’ sequences in cells of the tumor;
(3) the stimulation of cell proliferation by the ‘non-human’
genome (or part of it) in corresponding cell culture systems;
(4) the demonstration that the ‘non-human’ genome induces
proliferation and the malignant phenotype of the tumor. To
address whether MCV is causally relevant to MCC, additional
evidence is needed to elucidate tumorigenic potential of the
MCV T antigen.
In addition to the cancers known to be caused by human
viruses, there are many tumors in which a viral etiology is
suspected, including some hematopoietic malignancies, breast
cancer, colorectal cancer, basal cell carcinoma of the skin, and
lung cancers in non-smokers (Zur Hausen, 2009). Undoubtedly,
DTS analysis on whole transcriptomes of human tumors, in
conjunction with other approaches of the sort described above,
will help us to identify new clues or eliminate potential viral
etiologies. Despite the power of DTS in searching for viral
etiologies, there are some caveats that should be kept in mind: (1)
DTS relies on high database quality and unique features of non-
human sequences. Viral sequences that have been accidentally
deposited into human databases or viral sequences that are
indistinguishable from human transcripts will cause analyses
to fail. A specific subgroup of human endogenous retrovirus
(HERV-K) is suspected to be associated with multiple cancers
(Moyes et al., 2007). DTS against the human genome would
subtract out endogenous retroviral sequences as human and
thus fail to detect pathogenic sequences. (2) Viral transcripts
that lack polyadenylation sites, such as found in Flaviviridae
and Reoviridae, cannot be detected. (3) Viruses causing tumors
without gene expression, such by insertional mutagenesis, will
be missed. Thus, extra efforts should be made to overcome the
caveats of DTS analysis by combining with other methods for
virus discovery.
The invention of high throughput sequencing technology
developed massive transcriptome database generated from
various human cancers in the Cancer Genome Atlas (TCGA),
which could be a direct resource for DTS. Several studies
interrogated transcriptome sequencing data from nearly 4,000
different tumors generated within the TCGA consortium for the
presence of viral sequences by using the strategy similar to DTS
(Khoury et al., 2013; Tang et al., 2013). One of these studies
revealed a rare bladder cancer with BK polyomavirus integration
that expresses full length LT antigen (Tang et al., 2013) and also
identified a novel enterovirus in colon adenocarcinoma which
is unlikely to be oncogenic. The use of DTS to the expanding
transcriptome database in the TCGA may allow us to discover
the eighth human tumor virus in the near future.
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